Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Novo Nordisk Stock Slides After Obesity Drug Trial Disappoints
Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...
STAT2d
Novo Nordisk shares drop after next-gen obesity drug disappoints in diabetes trial
Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...
Novo Nordisk slashes Wegovy price for patients lacking insurance benefits
Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...
Verywell Health on MSN21h
Novo Nordisk Offers Wegovy for $499 a Month in Direct-to-Consumer Program
Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.
How a Novo Nordisk Foundation-funded project sparked ultra-processed food fight
The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the world understands ultra-processed foods, after more than 90 independent food ...
Fierce Pharma2d
Novo Nordisk invites people with Type 2 diabetes into their ‘Ozempic Eras’ in star-studded campaign
In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...
Levi & Korsinsky Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a ...